IE
ORMP icon

Israel Englander’s Oramed Pharmaceuticals ORMP Stock Holding History

Israel Englander’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Buy
21,861
+5,843
+36% +$23.3K ﹤0.01% 5488
2026
Q1 		$54.5K Buy
+16,018
New +$54.3K ﹤0.01% 5423
2025
Q1 		– Sell
-24,381
Closed -$59K – 6258
2024
Q4 		$59K Sell
24,381
-22,286
-48% -$53K ﹤0.01% 5568
2024
Q3 		$114K Buy
46,667
+27,210
+140% +$66.3K ﹤0.01% 5557
2024
Q2 		$50K Buy
+19,457
New +$46.2K ﹤0.01% 5416
2023
Q3 		– Sell
-78,620
Closed -$281K – 6431
2023
Q2 		$281K Sell
78,620
-87,150
-53% -$279K ﹤0.01% 4929
2023
Q1 		$361K Sell
165,770
-324,433
-66% -$1.03M ﹤0.01% 4797
2022
Q4 		$5.9M Sell
490,203
-12,828
-3% -$99.7K ﹤0.01% 2672
2022
Q3 		$3.26M Sell
503,031
-77,352
-13% -$626K ﹤0.01% 3301
2022
Q2 		$2.66M Buy
580,383
+216,823
+60% +$1.16M ﹤0.01% 3413
2022
Q1 		$3.15M Sell
363,560
-398,010
-52% -$4.08M ﹤0.01% 3444
2021
Q4 		$10.9M Buy
761,570
+692,384
+1,001% +$14.5M 0.01% 2063
2021
Q3 		$1.52M Sell
69,186
-132,034
-66% -$2.25M ﹤0.01% 4219
2021
Q2 		$2.69M Buy
201,220
+45,098
+29% +$516K ﹤0.01% 3587
2021
Q1 		$1.59M Buy
156,122
+132,605
+564% +$1.09M ﹤0.01% 3758
2020
Q4 		$100K Sell
23,517
-46,567
-66% -$152K ﹤0.01% 5021
2020
Q3 		$183 Buy
+70,084
New +$244K ﹤0.01% 4090
2020
Q2 		– Sell
-13,091
Closed -$40K – 4483
2020
Q1 		$40K Buy
+13,091
New +$57.4K ﹤0.01% 3685
2019
Q4 		– Sell
-15,772
Closed -$50K – 4519
2019
Q3 		$50K Buy
+15,772
New +$52.5K ﹤0.01% 4045
2018
Q1 		– Sell
-15,849
Closed -$143K – 3966
2017
Q4 		$143K Buy
+15,849
New +$152K ﹤0.01% 3596
2016
Q3 		– Sell
-16,811
Closed -$140K – 3518
2016
Q2 		$140K Buy
+16,811
New +$143K ﹤0.01% 2971
2016
Q1 		– Sell
-14,364
Closed -$123K – 3555
2015
Q4 		$123K Buy
+14,364
New +$109K ﹤0.01% 3211

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Israel Englander's ORMP Position: Q2 2026 in Review

Israel Englander increased its Oramed Pharmaceuticals (ORMP) stake by 36% in Q2 2026, buying an estimated $23.3K and bringing the position to 21,861 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #5488.

Israel Englander first reported a position in ORMP in Q4 2015 and has held it in 22 quarters since. The position peaked at $10.9M in Q4 2021. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Israel Englander held 21,861 shares of Oramed Pharmaceuticals worth $105K as of Q2 2026.
  • Israel Englander bought 5,843 Oramed Pharmaceuticals shares in Q2 2026, an estimated $23.3K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5488 holding.
  • Israel Englander first reported a position in Oramed Pharmaceuticals in Q4 2015 and has held it in 22 quarters since.
  • Israel Englander's Oramed Pharmaceuticals position peaked at $10.9M in Q4 2021.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.